Back to top

Analyst Blog

Roche (RHHBY - Analyst Report) recently announced an alliance with Isis Pharmaceuticals, Inc (ISIS - Analyst Report) to develop therapies for Huntington's disease (HD).

This alliance will combine Isis’ antisense oligonucleotide (ASO) technology with Roche's scientific expertise to develop neurodegenerative therapeutics for treating HD.

Isis develops antisense drug discovery programs targeting cardiovascular, severe and rare neurologic and metabolic diseases and cancer.

In addition, Roche will combine its proprietary brain shuttle technology with Isis ASO technology to enable systemic administration of antisense drugs for treating asymptomatic patients.

As per the agreement, Roche will make an upfront payment of $30 million to Isis. The total payment comprising license fee and pre- and post-licensing milestone payments is expected to touch $362 million including potential commercial milestone payments up to $80 million. 

Additionally, Isis is eligible to receive royalties on sales of the drugs whereas Roche has the option to license the drugs from Isis through the completion of the first phase I trial. Before Roche exercises this option, Isis will be responsible for discovering and developing of an antisense drug targeting huntingtin (HTT) protein in collaboration with Roche.

Once Roche exercises its option, it will be responsible for the global development, regulatory and commercialization activities for all drugs resulting from the alliance. As per Roche, currently there is no effective cure for HD.

We are positive on the deal with Isis as the market for HD represents a huge unmet medical need.

The deal comes close on the heels of the Japanese approval of the subcutaneous injectable version of Roche’s rheumatoid arthritis (RA) drug Actemra (tocilizumab). The subcutaneous version of the drug has been approved for treating RA patients who have not responded adequately to one or more existing medications for the disease.

Actemra primarily faces competition from AbbVie Inc.’s (ABBV - Analyst Report) Humira in the RA space.

Roche, a large cap pharma company, carries a Zacks Rank #4 (Sell). Favorably placed large cap pharma stocks include Novartis (NVS - Analyst Report) with a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%